Open Access Could Transform Drug Discovery: A Case Study of JQ1

Abstract Introduction: The cost to develop a new drug from target discovery to market is a staggering $1.8 billion, largely due to the very high attrition rate of drug candidates and the lengthy transition times during development. Open access is an emerging model of open innovation that places no restriction on the use of information and has the potential to accelerate the development of new drugs. Areas Covered: To date, no quantitative assessment has yet taken place to determine the effects and viability of open access on the process of drug translation. This need is addressed within this study. The literature and intellectual property landscapes of the drug candidate JQ1, which was made available on an open access basis when discovered, and conventionally developed equivalents that were not are compared using the Web of Science and Thomson Innovation software, respectively. Expert opinion: Results demonstrate that openly sharing the JQ1 molecule led to a greater uptake by a wider and more multi-disciplinary research community. A comparative analysis of the patent landscapes for each candidate also found that the broader scientific diaspora of the publically released JQ1 data enhanced innovation, evidenced by a greater number of downstream patents filed in relation to JQ1. The authors’ findings counter the notion that open access drug discovery would leak commercial intellectual property. On the contrary, JQ1 serves as a test case to evidence that open access drug discovery can be an economic model that potentially improves efficiency and cost of drug discovery and its subsequent commercialization.

[1]  H. Chesbrough,et al.  Beyond High Tech: Early Adopters of Open Innovation in Other Industries , 2006 .

[2]  L Lasagna,et al.  The development and regulation of new medications. , 1978, Science.

[3]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[4]  Nancy Fullman,et al.  Global malaria mortality between 1980 and 2010: a systematic analysis , 2012, The Lancet.

[5]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[6]  Henry Chesbrough,et al.  The Logic of Open Innovation: Managing Intellectual Property , 2003 .

[7]  David Brindley,et al.  Pharmaceutical industry: Investors unfazed by drug-patent expiry , 2012, Nature.

[8]  Henry Chesbrough,et al.  How open innovation can help you cope in lean times. , 2009 .

[9]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[10]  Christopher J. Schofield,et al.  A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response , 2012, Nature.

[11]  Mark Kessel,et al.  The problems with today's pharmaceutical business—an outsider's view , 2011, Nature Biotechnology.

[12]  Bernard H. Munos,et al.  Can open-source R&D reinvigorate drug research? , 2006, Nature Reviews Drug Discovery.

[13]  M. Heller,et al.  Can Patents Deter Innovation? The Anticommons in Biomedical Research , 1998, Science.

[14]  Bethan Hughes,et al.  Harnessing open innovation , 2009, Nature Reviews Drug Discovery.

[15]  Bethany Kinseth Runge,et al.  Breaking Down Translation Barriers: Investigator’s Perspective , 2014, Science Translational Medicine.

[16]  C. Bountra,et al.  The Structural Basis of ZMPSTE24-Dependent Laminopathies , 2013, Science.

[17]  R. M. Owen,et al.  An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.

[18]  Henry Chesbrough,et al.  Open Innovation: The New Imperative for Creating and Profiting from Technology , 2003 .

[19]  T. Willson,et al.  Open access chemical and clinical probes to support drug discovery. , 2009, Nature chemical biology.

[20]  Ravi Anand,et al.  Barriers to Alzheimer Disease Drug Discovery and Drug Development in the Pharmaceutical Industry , 2002, Alzheimer disease and associated disorders.

[21]  M. Rawlins.  Cutting the cost of drug development? , 2004, Nature Reviews Drug Discovery.

[22]  J. Irwin,et al.  Identifying mechanism-of-action targets for drugs and probes , 2012, Proceedings of the National Academy of Sciences.

[23]  P. Woll,et al.  Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate , 2008, Therapeutics and clinical risk management.

[24]  R Brookmeyer,et al.  Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. , 1998, American journal of public health.

[25]  Fredric Cohen,et al.  Macro trends in pharmaceutical innovation , 2005, Nature Reviews Drug Discovery.

[26]  Susie Stephens,et al.  Is open innovation the way forward for big pharma? , 2010, Nature Reviews Drug Discovery.

[27]  Anthony R Scialli,et al.  Thalidomide: the tragedy of birth defects and the effective treatment of disease. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[28]  J Rees,et al.  Intellectual property , 2001, The Lancet.

[29]  Bernard H. Munos,et al.  How to Revive Breakthrough Innovation in the Pharmaceutical Industry , 2011, Science Translational Medicine.

[30]  A. Duhme-Klair,et al.  The background, discovery and clinical development of BCR-ABL inhibitors. , 2013, Drug discovery today.

[31]  M. Bunnage.  Getting pharmaceutical R&D back on target. , 2011, Nature chemical biology.

[32]  Wen Hwa Lee,et al.  Open Access Target Validation Is a More Efficient Way to Accelerate Drug Discovery , 2015, PLoS biology.

[33]  Gareth J Waldron,et al.  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling , 2012, Nature Reviews Drug Discovery.

[34]  Alex Matter,et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.

[35]  Anne Corbett,et al.  Drug repositioning in Alzheimer's disease. , 2015, Frontiers in bioscience.

[36]  Jeremy N. Burrows,et al.  The Open Access Malaria Box: A Drug Discovery Catalyst for Neglected Diseases , 2013, PloS one.

[37]  D. Gann,et al.  How open is innovation , 2010 .

[38]  D. Fabbro,et al.  Imatinib: a selective tyrosine kinase inhibitor. , 2002, European journal of cancer.

[39]  John L. LaMattina,et al.  The impact of mergers on pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[40]  J. Greene,et al.  Reform, regulation, and pharmaceuticals--the Kefauver-Harris Amendments at 50. , 2012, The New England journal of medicine.

[41]  I. Cockburn,et al.  The changing structure of the pharmaceutical industry. , 2004, Health affairs.

[42]  Roger M. Stein,et al.  Commercializing biomedical research through securitization techniques , 2012, Nature Biotechnology.

[43]  Francisco Cervantes,et al.  The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. , 2013, Blood.

[44]  J. Cummings,et al.  Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.

[45]  B. Munos.  Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.

[46]  Richard J Maude,et al.  The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia , 2009, Malaria Journal.

[47]  Steven M. Opal,et al.  Role of Toll-Like Receptors in Infection and Immunity , 2012, Drugs.

[48]  Kim Bure,et al.  The global intellectual property landscape of induced pluripotent stem cell technologies , 2014, Nature Biotechnology.

[49]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[50]  Stefan Knapp,et al.  Recently targeted kinases and their inhibitors-the path to clinical trials. , 2014, Current opinion in pharmacology.